Shipping to United States We Offer Worldwide Shipping
Login Wishlist

Apigenin

$64

  • Brand : BIOFRON

  • Catalogue Number : BD-D1337

  • Specification : 98%(HPLC)

  • CAS number : 520-36-5

  • Formula : C15H10O5

  • Molecular Weight : 270.24

  • PUBCHEM ID : 5280443

  • Volume : 20MG

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-D1337

Analysis Method

HPLC,NMR,MS

Specification

98%(HPLC)

Storage

2-8℃

Molecular Weight

270.24

Appearance

Yellow crystal

Botanical Source

Apium graveolens var.dulce/Found free or as glycosides in the stems, roots, leaves, seeds or fruit of a very wide range of plant spp. Found also in some fossil leaf tissues

Structure Type

Flavones/Flavanones

Category

Standards;Natural Pytochemical;API

SMILES

C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O

Synonyms

5,7,4'-trihydroxyflavone/apigenol/Versuline/Versulin/262620/4',5,7-Trihydroxyflavone/CHAMOMILE/Celery seed extract/C.I. NATURAL YELLOW 1/T66 BO EVJ CR DQ& GQ IQ/Apigenine/4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxyphenyl)-/5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one/Apigenin/Pelargidenone

IUPAC Name

5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one

Applications

Apigenin is a competitive CYP2C9 inhibitor with a Ki of 2 μM.

Density

1.5±0.1 g/cm3

Solubility

Methanol

Flash Point

217.1±23.6 °C

Boiling Point

555.5±50.0 °C at 760 mmHg

Melting Point

>300 °C(lit.)

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2932990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:520-36-5) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

27766890

Abstract

Apigenin, a natural flavone, is widely distributed in plants such as celery, parsley and chamomile. It is present principally as glycosylated in nature. Higher intake of apigenin could reduce the risk of chronic diseases. It has gained particular interest in recent years as a beneficial, health-promoting agent with low intrinsic toxicity. Areas covered: This review summarizes and the absorption, distribution, metabolism and excretion (ADME) properties of apigenin, and drug-drug interaction of apigenin. Expert opinion: Since apigenin is a bioactive plant flavone and is widely distributed in common food, its consumption through the diet is recommended. Apigenin-enriched drugs are better for some chronic diseases, but may affect animal and human health if present in the daily diet. Dietary or therapeutic apigenin has value as a good cellular regulator in cancer, especially cancers of the gastrointestinal tract. Due to apigenin’s limitations on absorption and bioavailability, novel carriers would need to be developed to enhance the oral bioavailability of apigenin. Further research about its ADME properties and drug-drug interactions are needed before apigenin can be brought to clinical trials.

KEYWORDS

ADME; Apigenin; interaction; pharmacokinetic

Title

Pharmacokinetic properties and drug interactions of apigenin, a natural flavone.

Author

Tang D1, Chen K1, Huang L1,2, Li J1,2.

Publish date

2017 Mar

PMID

30875872

Abstract

Several plant bioactive compounds have exhibited functional activities that suggest they could play a remarkable role in preventing a wide range of chronic diseases. The largest group of naturally-occurring polyphenols are the flavonoids, including apigenin. The present work is an updated overview of apigenin, focusing on its health-promoting effects/therapeutic functions and, in particular, results of in vivo research. In addition to an introduction to its chemistry, nutraceutical features have also been described. The main key findings from in vivo research, including animal models and human studies, are summarized. The beneficial indications are reported and discussed in detail, including effects in diabetes, amnesia and Alzheimer’s disease, depression and insomnia, cancer, etc. Finally, data on flavonoids from the main public databases are gathered to highlight the apigenin’s key role in dietary assessment and in the evaluation of a formulated diet, to determine exposure and to investigate its health effects in vivo.

KEYWORDS

apigenin; cancer; chronic diseases; diabetes; flavonoids

Title

The Therapeutic Potential of Apigenin.

Author

Salehi B1, Venditti A2, Sharifi-Rad M3, Kręgiel D4, Sharifi-Rad J5, Durazzo A6, Lucarini M7, Santini A8, Souto EB9,10, Novellino E11, Antolak H12, Azzini E13, Setzer WN14, Martins N15,16.

Publish date

2019 Mar 15

PMID

29055745

Abstract

Neurodegenerative disorders (NDDs) such as Alzheimer’s and Parkinson’s diseases are the most common age-related pathologies that affect millions of people all over the world. To date, effective therapy for NDDs is not available and current approaches to disease management include neuroprotection strategy with a hope of maintaining and enhancing the function of survising neurons. Of course, such an approach by its own will not offer a cure but is likely to delay the disease progression by ameliorating the increase of neurotoxic agents such reactive oxygen species (ROS) as well as the associated inflammatory cascades. In this regard, natural products including flavonods that offer neuroprotection through multiple mechanisms have gained a lot of interest in recent years. In this communication, evidences from the various experimental models and clinical trials on the therapeutic potential of one promising flavonod, apigenin, is presented. Its chemistry, mechanism of action and potential benefits in the various examples of NDDs are discussed in the light of drug discovery aspects.

Copyright © 2017 Elsevier Ltd. All rights reserved.

KEYWORDS

Alzheimer’s disease; Apigenin; Flavonoids; Neuroprotection; Parkinson’s disease

Title

Apigenin as neuroprotective agent: Of mice and men.

Author

Nabavi SF1, Khan H2, D'onofrio G3, Šamec D4, Shirooie S5, Dehpour AR6, Arguelles S7, Habtemariam S8, Sobarzo-Sanchez E9.

Publish date

2018 Feb